Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | Wnk2 |
| Gene Name: | WNK2 |
| Protein Full Name: | Serine/threonine-protein kinase WNK2 |
| Alias: | Antigen NY-CO-43; EC 2.7.11.1; KIAA1760; NY-CO-43; P,OKcl.13; P/OKcl.13; PRKWNK2; Protein kinase with no lysine 2; Protein kinase, lysine-deficient 2; SDCCAG43; Serologically defined colon cancer antigen 43; WNK lysine deficient protein kinase 2 |
| Mass (Da): | 242676 |
| Number AA: | 2297 |
| UniProt ID: | Q9Y3S1 |
| Locus ID: | 65268 |
| COSMIC ID: | WNK2 |
| Gene location on chromosome: | 9q22.31 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 20260 |
| Percent of cancer specimens with mutations: | 1.49 |
| Normal role description: | WNK2 is a serine/threonine kinase. It activates sodiu-coupled chloride cotransporters and inhibits potassium-coupled chloride cotransporters. It is also involved in reducing ERK1/2 activation. ERK1/2 expression can also increase through activation of of MEK1 via Rac1-mediate PAK1 activation. Its roles are in regulation of cell cycle progression, proliferation and electrolyte balance. Loss of expression is found in gliomas and meningioma and facilitate increased cell cycle progression and proliferation. |